AIDS Reader

July 08, 2011

May 04, 2011

#mainLogin {width : 700px;background: url(http://imaging.cmpmedica.com/all/gradient-grey-bg2.png) repeat-x bottom;border : 1px solid #cccccc;}#mainLogin h1 {font-size: 1.6em;color: rgb(255, 255, 255);background-color: rgb(20, 72, 146);padding : 5px;text-align:left;}.largeText {font-size : 1.4em;}#mainLogin ul {list-style-type: disc;list-style-position: outside;padding-left : 20px;}#mainLogin label {color:#666666;}#passwordLink {font-size : 12px;}#login {color:white;background-color:#144892;}td.left, td.right, .alert {padding : 12px;}td.right {border-left : 1px solid #cccccc;}

February 09, 2011

A Roster of HIV/AIDS-Related Resources

July 22, 2010

June 10, 2010

How likely is it that an HIV patient's infection will become less severe? A bioinformatics researcher at Drexel University has developed a competition on Kaggle that asks participants to find the markers in an HIV sequence that could predict a change in severity of infection.

February 03, 2010

In 2006, the CDC recommended “opt-out” routine HIV testing in all health care encounters for persons 13 to 64 years of age. While this recommendation has garnered some support, concerns about the feasibility of such routine testing in a busy office without disrupting patient care has persisted. We report the results of a pilot study to determine the feasibility of routine testing in a busy urban clinic.

May 30, 2009

A 30-year-old white man with HIV infection since September 2004 presented to his infectious disease physician in January 2007 to restart his antiretroviral therapy. Three months earlier, he had discontinued all of his antiretroviral medications because of his loss of health insurance. He remained asymptomatic during this period, with the exception of some mild oral candidiasis. At the time of restarting his antiretroviral therapy, his CD4+ cell count was 264/µL and test results were positive for syphilis (rapid plasma reagent [RPR] titer of 1:128, confirmed with a fluorescent treponemal antibody absorption test).

May 29, 2009

Tenofovir disoproxil fumarate is extensively used for treatment of HIV infection. In addition, tenofovir has recently obtained FDA approval for treatment of hepatitis B, and it can therefore be assumed that this drug will be increasingly used in non–HIV-infected persons as well. Although the risk for nephrotoxicity with this agent is low, its widespread use will no doubt lead to more episodes of renal impairment in patients worldwide. It is important to identify those patients for whom tenofovir should not be used or, at the least, identify those patients, both HIV-infected and non–HIV-infected, for whom renal function should be more closely monitored during tenofovir use.

May 02, 2009

More Listings

May 01, 2009

Anal cancer has become one of the most common non–AIDS-defining tumors in HIV-infected persons.1,2 The incidence of anal intraepithelial neoplasia (AIN) is also markedly increased in HIV-positive men,3 particularly those who have sex with men (MSM), despite the introduction of highly active antiretroviral therapy.4